Saturday Night Live cast member Pete Davidson has had a roller-coaster year. In June, it was announced that he was engaged to pop star Ariana Grande. By October, the engagement was off. Then he received harsh criticism over a bad joke he made about Texas congressional candidate Dan Crenshaw — a Navy Seal veteran who had lost an eye in Afghanistan. A week later, congressman-elect Crenshaw accepted Davidson’s apology and took a few swipes back at him on SNL’s Weekend Update.
But this past year was, unfortunately, emblematic of Davidson’s life. Pete lost his father, a New York City firefighter at the World Trade Center on 9/11. His father’s death took a heavy toll on him. In a New York Times article, his mother Amy said, “It was sad how sad he was growing up … In school, he would act out.” “At one point, he said, he ripped all his hair out until he was bald. He became a ‘lab rat’ for doctors studying the children of Sept. 11 victims. ‘It was overwhelming,’ he said.”
Davidson was diagnosed with Crohn’s disease when he was 17 or 18. In a recent interview with Nicki Swift, he explained, “Whenever I wake up, if I don’t hit the bowl or something, it’ll feel like someone punched me in the stomach.” He’s been treated with oral drugs as well as the monoclonal antibody drug infliximab (Remicade). He’s tried nutritional therapy, but Davidson told the Breakfast Club crew that “healthy stuff” doesn’t help him, but instead “just goes right through” his body.
But he did eventually find something that seemed to help. In an interview with High Times Davidson said:
“And I found that the medicines that the doctors were prescribing me and seeing all these doctors and trying new things … weed [cannabis] would be the only thing that would help me eat.”
“My stomach would be in pain all day, and I wouldn’t be able to eat, but then I’d smoke and I can eat and do my shows … I wouldn’t be able to do SNL if I didn’t smoke weed. I wouldn’t be able to do anything really. Me performing not high has gone awful. It’s awful for me because I don’t feel well.”
What is Crohn’s Disease?
Crohn’s disease (CD) is one of two varieties of inflammatory bowel disease or IBD (ulcerative colitis being the other). Both are disorders that involve chronic inflammation of the digestive tract. CD can involve any portion of the digestive tract, from the mouth to anus, however, it most commonly affects the small intestine and proximal colon. Unlike ulcerative colitis, in which the inflammation is relatively superficial, inflammation in CD can involve the entire thickness of intestine.
Researchers estimate that more than half a million people in the United States have Crohn’s disease. Studies show that, over time, Crohn’s disease has become more common in the United States and other parts of the world. The reason for this increase is unknown.
Crohn’s disease can develop in people of any age and is more likely to develop in people
The most common symptoms of Crohn’s disease are
Other symptoms include
What are the complications of Crohn’s disease?
Complications of Crohn’s disease can include the following:
How is Crohn’s disease treated?
Although there is yet no cure for Crohn’s disease, there are many drugs that can reduce symptoms. According to the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), drugs to treat Crohn’s disease include:
Aminosalicylates contain 5-aminosalicylic acid (5-ASA), which helps control inflammation. Doctors use aminosalicylates to treat people newly diagnosed with Crohn’s disease who have mild symptoms. Aminosalicylates include balsalazide, mesalamine, olsalazine, and sulfasalazine.
Corticosteroids are prescribed for people with moderate to severe symptoms. Corticosteroids include budesonide, hybrocortisone, methylprednisolone, and prednisone.
Immunomodulators reduce immune system activity, resulting in less inflammation. Immunomodulators can take several weeks to 3 months to start working. Immunomodulators include 6-mercaptopurine, azathioprine, cyclosporine, and methotrexate.
Biologic therapies target proteins made by the immune system. Neutralizing these proteins decreases inflammation in the intestines.
Even with these medicines, however, surgery is often needed to treat complications.
The role of cannabinoids in the treatment of Crohn’s Disease
People have used cannabis for a variety of health conditions for at least 3,000 years. More recently, individual components of marijuana or similar synthetic substances, called cannabinoids, have also been used for health purposes. Cannabinoids are active chemicals in cannabis that cause drug-like effects throughout the body, including the central nervous system and the immune system. The main active cannabinoid in cannabis is delta-9-THC. Another active cannabinoid is cannabidiol (CBD), which may relieve pain, lower inflammation, and decrease anxiety without causing the “high” of delta-9-THC.
Research into the effects of cannabinoids lead to the discovery of the endocannabinoid system (ECS). The ECS is a biological system composed of endocannabinoids, which are endogenous lipid-based neurotransmitters that bind to cannabinoid receptors, the cannabinoid receptor proteins that are expressed throughout the central and peripheral nervous systems and the enzymes responsible for synthesis and degradation of the endocannabinoids. ECS has emerged as an important neuromodulatory system.
Endocannabinoids exert their effects by finding to specific receptors on their target cells. There are two main types of cannabinoid receptors, CB1 and CB2. CB1 receptors, the most predominant form, are found mostly in neurons in the CNS and PNS, while CB2 receptors are commonly identified in immune cells. The best characterized endocannabinoids are N-arachidonoylethanolamide (anandamide) and two-arachidonolyl glycerol (2-AG).
In the gastrointestinal system, CB1 and CB2 are found in all layers of the intestinal wall. According to Ahmed and Katz, “Cannabinoids predominately mediate inhibitory pathways in the GI tract through reduction of vagal cholinergic tone. CB2 modulate inflammation, whereas CB1 control central functions, including pain control, satiety, nausea, and vomiting.”
Surveys by Garcia-Planella, Lal, and Allegretti found significant proportions of patients with IBD use complementary and alternative medicine (CAM) for additional management of symptoms. Ten to 16% of patients reported active use, while 32-50% of patients reported lifetime use of medical cannabis specifically for symptom relief of IBD. The patients cite ineffectiveness of current therapy, fewer side effects, and a sense of gaining control over their illness as motives for CAM use. It should be noted that the surveys also showed that patients infrequently reported their cannabis use to their physicians.
Is there any scientific evidence to support the use of cannabis in IBD? A 2014 Canadian study by Storr et al had 313 patients with IBD seen at the University of Calgary fill out a questionnaire covering motives, pattern of use, and subjective beneficial and adverse effects associated with self-administration of cannabis. “Cannabis had been used by 17.6% of respondents specifically to relieve symptoms associated with their IBD, the majority by inhalational route (96.4%). Patients with IBD reported that cannabis improved abdominal pain (83.9%), abdominal cramping (76.8%), joint pain (48.2%), and diarrhea (28.6%),” However, they also found that in patients with CD with a prolonged use of cannabis (>6 months), there was an increased history of surgery. But they acknowledge that it was not possible to associate the time of cannabis use with surgery, so temporal relationships or causation could not be made.
Naftali and her colleagues in Israel have presented several studies on the response of patients with CD to cannabis. The first, a retrospective observational study in 2011, interviewed 30 patients with CD who had been prescribed cannabis. Disease activity before and after cannabis was estimated using a Harvey Bradshaw index (a simplification of the Crohn’s Disease Activity Index-CDAI). They found that “Of the 30 patients 21 improved significantly after treatment with cannabis. The average Harvey Bradshaw index improved from 14 Â± 6.7 to 7 Â± 4.7 (P < 0.001). The need for other medication was significantly reduced. Fifteen of the patients had 19 surgeries during an average period of 9 years before cannabis use, but only 2 required surgery during an average period of 3 years of cannabis use.
Her second study in 2014, was a prospective placebo-controlled study with 21 patients with CD who did not respond to therapy with steroids, immunomodulators, or anti-tumor necrosis factor-Î± agents. They were divided into two groups, one given cannabis, twice daily for 8 weeks, in the form of THC-containing cigarettes or placebo containing cannabis flowers from which the THC had been extracted. “Complete remission (CDAI score, <150) was achieved by 5 of 11 subjects in the cannabis group (45%) and 1 of 10 in the placebo group (10%; P = .43). A clinical response (decrease in CDAI score of >100) was observed in 10 of 11 subjects in the cannabis group and 4 of 10 in the placebo group. Three patients in the cannabis group were weaned from steroid dependency. Subjects receiving cannabis reported improved appetite and sleep, with no significant side effects.
At the United European Gastroenterology conference in Vienna, October 2018, Naftali reported her latest findings. Forty-six people with moderately severe CD were randomized to receive wither cannabis oil (15% cannabidiol and 4% THC) or placebo for 8 weeks.” The group receiving the cannabis oil had a significant reduction in their Crohn’s disease symptoms compared with the placebo group, and 65%met strict criteria for clinical remission (versus 35% of the placebo recipients).”
But the most surprising aspect of the study came when they measured inflammation in the gut using endoscopy and measuring inflammatory markers. “We have previously demonstrated that cannabis can produce measurable improvements in Crohn’s disease symptoms but, to our surprise, we saw no statistically significant improvements in endoscopic scores or in the inflammatory markers we measured in the cannabis oil group compared with the placebo group,” said Dr. Naftali. “We know that cannabinoids can have profound anti-inflammatory effects, but this study indicates that the improvement in symptoms may not be related to these anti-inflammatory properties.”
Although the early scientific evidence is promising, larger scale, longer follow-up trials are needed.
Do any of you have any patients using cannabis as a complementary treatment for Crohn’s disease? What has been your experience?
Michele R. Berman, MD, and Mark S. Boguski, MD, PhD, are a wife and husband team of physicians who have trained and taught at some of the top medical schools in the country including Harvard, Johns Hopkins, and Washington University in St. Louis. Their mission is both a journalistic and educational one: to report on common diseases affecting uncommon people and summarize the evidence-based medicine behind the headlines.